Prothena

Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena Corporation (NASDAQ: PRTA), a biopharmaceutical company specializing in protein dysregulation, to acquire PRX019, a promising candidate for neurodegenerative diseases. The agreement follows PRX019’s attainment of Investigational New Drug (IND) status in the previous year. Under…